Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability
Joanna Narbutt,1 Michał Niedźwiedź,1 Aleksandra Lesiak,1 Justyna Ceryn,1,2 Małgorzata Skibińska1 1Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland; 2International Doctoral Sch...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-02-01
|
| Series: | Patient Preference and Adherence |
| Subjects: | |
| Online Access: | https://www.dovepress.com/secukinumab-for-the-treatment-of-psoriasis-in-pediatrics-patient-selec-peer-reviewed-fulltext-article-PPA |
| _version_ | 1797904622967324672 |
|---|---|
| author | Narbutt J Niedźwiedź M Lesiak A Ceryn J Skibińska M |
| author_facet | Narbutt J Niedźwiedź M Lesiak A Ceryn J Skibińska M |
| author_sort | Narbutt J |
| collection | DOAJ |
| description | Joanna Narbutt,1 Michał Niedźwiedź,1 Aleksandra Lesiak,1 Justyna Ceryn,1,2 Małgorzata Skibińska1 1Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland; 2International Doctoral School of the Medical University of Lodz, Lodz, PolandCorrespondence: Michał Niedźwiedź, Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, gen. Karola Kniaziewicza 1/5, Lodz, 91-347, Poland, Tel +48 690 529 430, Email michal.niedzwiedz@umed.lodz.plAbstract: Psoriasis (PsO) is a chronic, systemic, immune-mediated inflammatory skin disease affecting 1% to 5% population worldwide. In one-third of patients, the first symptoms of PsO manifest in childhood, with a mean age of nine years. Psoriasis in children under 16 years of age constitutes 4% of dermatological problems in this age group. Chronic inflammation of the skin observed in PsO is associated with a development of potentially serious comorbidities, including psoriatic arthritis, hypertension, metabolic syndrome, cardiovascular diseases, inflammatory bowel disease, depression and anxiety. It is reported that among children with psoriasis between 5 and 16 years of age health-related quality of life is reduced by 30.5%. Early diagnosis and effective treatment are crucial in pediatric psoriatic patients to avoid future complications and stigmatization. Treatment for psoriasis consists of a range of topical medications, phototherapy and non-biologic and biologic systemic therapies. Approved biologics for PsO in pediatric patients include etanercept, adalimumab, ustekinumab, ixekizumab and secukinumab. Secukinumab, a recombinant, fully human monoclonal antibody targeting IL-17A, was approved by the EMA (2020) and FDA (2021) in pediatric patients above 6 years of age for the treatment of moderate to severe plaque psoriasis who are candidates for systemic therapy. This review discusses the selection and acceptability of secukinumab in children with psoriasis.Keywords: pediatric psoriasis, psoriasis vulgaris, secukinumab, acceptability |
| first_indexed | 2024-04-10T09:51:55Z |
| format | Article |
| id | doaj.art-4a7fb66466e4463792675b255c653500 |
| institution | Directory Open Access Journal |
| issn | 1177-889X |
| language | English |
| last_indexed | 2024-04-10T09:51:55Z |
| publishDate | 2023-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Patient Preference and Adherence |
| spelling | doaj.art-4a7fb66466e4463792675b255c6535002023-02-16T18:07:27ZengDove Medical PressPatient Preference and Adherence1177-889X2023-02-01Volume 1742143181685Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and AcceptabilityNarbutt JNiedźwiedź MLesiak ACeryn JSkibińska MJoanna Narbutt,1 Michał Niedźwiedź,1 Aleksandra Lesiak,1 Justyna Ceryn,1,2 Małgorzata Skibińska1 1Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland; 2International Doctoral School of the Medical University of Lodz, Lodz, PolandCorrespondence: Michał Niedźwiedź, Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, gen. Karola Kniaziewicza 1/5, Lodz, 91-347, Poland, Tel +48 690 529 430, Email michal.niedzwiedz@umed.lodz.plAbstract: Psoriasis (PsO) is a chronic, systemic, immune-mediated inflammatory skin disease affecting 1% to 5% population worldwide. In one-third of patients, the first symptoms of PsO manifest in childhood, with a mean age of nine years. Psoriasis in children under 16 years of age constitutes 4% of dermatological problems in this age group. Chronic inflammation of the skin observed in PsO is associated with a development of potentially serious comorbidities, including psoriatic arthritis, hypertension, metabolic syndrome, cardiovascular diseases, inflammatory bowel disease, depression and anxiety. It is reported that among children with psoriasis between 5 and 16 years of age health-related quality of life is reduced by 30.5%. Early diagnosis and effective treatment are crucial in pediatric psoriatic patients to avoid future complications and stigmatization. Treatment for psoriasis consists of a range of topical medications, phototherapy and non-biologic and biologic systemic therapies. Approved biologics for PsO in pediatric patients include etanercept, adalimumab, ustekinumab, ixekizumab and secukinumab. Secukinumab, a recombinant, fully human monoclonal antibody targeting IL-17A, was approved by the EMA (2020) and FDA (2021) in pediatric patients above 6 years of age for the treatment of moderate to severe plaque psoriasis who are candidates for systemic therapy. This review discusses the selection and acceptability of secukinumab in children with psoriasis.Keywords: pediatric psoriasis, psoriasis vulgaris, secukinumab, acceptabilityhttps://www.dovepress.com/secukinumab-for-the-treatment-of-psoriasis-in-pediatrics-patient-selec-peer-reviewed-fulltext-article-PPApediatric psoriasispsoriasis vulgarissecukinumabacceptability |
| spellingShingle | Narbutt J Niedźwiedź M Lesiak A Ceryn J Skibińska M Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability Patient Preference and Adherence pediatric psoriasis psoriasis vulgaris secukinumab acceptability |
| title | Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability |
| title_full | Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability |
| title_fullStr | Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability |
| title_full_unstemmed | Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability |
| title_short | Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability |
| title_sort | secukinumab for the treatment of psoriasis in pediatrics patient selection and acceptability |
| topic | pediatric psoriasis psoriasis vulgaris secukinumab acceptability |
| url | https://www.dovepress.com/secukinumab-for-the-treatment-of-psoriasis-in-pediatrics-patient-selec-peer-reviewed-fulltext-article-PPA |
| work_keys_str_mv | AT narbuttj secukinumabforthetreatmentofpsoriasisinpediatricspatientselectionandacceptability AT niedzwiedzm secukinumabforthetreatmentofpsoriasisinpediatricspatientselectionandacceptability AT lesiaka secukinumabforthetreatmentofpsoriasisinpediatricspatientselectionandacceptability AT cerynj secukinumabforthetreatmentofpsoriasisinpediatricspatientselectionandacceptability AT skibinskam secukinumabforthetreatmentofpsoriasisinpediatricspatientselectionandacceptability |